European Medicines Agency: A second chance to psychedelics
E.M.A./European Medicines Agency. - March 16, 2023
The European Medicines Agency recognizes that psychedelic-assisted therapy (such as ketamine) is promising for dealing with various mental health conditions. Over the past decade, there has been a shift in the way psychedelics are viewed, with academics and researchers showing a renewed interest in what is called psychedelic-assisted therapy, when single-dose psychedelics are used in combination with psychotherapy. Research has focused on the use of psychedelic-assisted therapy against resistant depression, post-traumatic stress disorder (PTSD) and substance abuse.
https://www.linkedin.com/pulse/second-chance-psychedelics-european-medicines-agency/
